** Shares of Avadel Pharmaceuticals AVDL.O fall ~25% to $8.01 premarket
** Late on Wednesday AVDL forecast 2025 rev in the range of $240 mln to $260 mln
** Analysts on average estimate total revenue of about $267.6 mln -LSEG data
** At least two brokerages cut PT on AVDL following the disappointing 2025 outlook
** H.C.Wainwright analysts expect a slower revenue ramp up for its sleep disorder drug Lumryz
** Up to last close, stock down ~32% over the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。